BioXcel Rallies 27% on Expanded Schizophrenia Study and Positive FDA Interaction
BioXcel Therapeutics, Inc. (BTAI) surged 27.48% to lead the PRISM Emerging Mental Health Index after announcing a pivotal update to its TRANQUILITY III trial evaluating BXCL501 in schizophrenia-related agitation. The FDA supported the company’s amended protocol to incorporate both bipolar disorder and schizophrenia cohorts under a single Phase 3 study, streamlining regulatory efforts and expanding market potential. BioXcel also reaffirmed plans to submit a supplemental NDA in 2026.
NeuroSense Falls 29% Despite Advancing Toward Pivotal ALS Trial
NeuroSense Therapeutics Ltd. (NRSN) dropped 29.45%, weighing heavily on the PRISM Emerging Biotech Index, despite announcing meaningful progress toward a pivotal Phase 3 trial of its ALS drug candidate PrimeC. While the company showcased promising data from its PARADIGM Phase 2b trial, highlighting a 74% improvement in overall survival and 40% slower functional decline, investors reacted negatively to lingering financial concerns, ongoing partnership negotiations, and the $4.7 million operating loss for H1 2025. A share price retreat followed recent dilution from private placements, despite their drug’s advancing clinical profile.
Other PRISM Mid-Day Movers:
• Mullen Automotive, Inc. (MULN) down 29.13%
• Psyence Biomedical Ltd. (PBM) down 29.22%
• 374Water, Inc. (SCWO) down 18.63%
• Riot Platforms, Inc. (RIOT) down 16.14%
The post PRISM Mid-Day Movers: Mental Health Momentum and Biotech Setbacks Define Market Sentiment appeared first on PRISM MarketView.
